Spotlight On CSL Revenue Targets
CSL is highly likely to be looking for other avenues of revenue to meet targets in FY21, given a prospective shortfall in plasma collections.
Read More
Csl Limited
Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
Videos
Videos coming soon for Csl Limited.
All Csl Limited Content
News
CSL Delivers Again With Higher Profit, Increased Dividend
Thumbs up from investors for CSL’s latest full-year results and confident outlook for the 2020-21 financial year. Australia’s global pharma giant said yesterday it is looking for an 8% rise in earnings for 2020-21 after reporting record sales and a record dividend for 2019-20, despite all the uncertainties caused by the COVID-19 pandemic.
Read More
Do Less Risky Stock Market Exposures Really Exist?
With a sense of raw panic descending on global stock markets, the question is whether there are any truly safe havens in terms of remaining exposed to equities?
Read More
“Well-Positioned” CSL Lifts H1 Earnings 11%
A rather ho-hum reaction from investors yesterday to another solid result from CSL, the current market darling and most expensive share on the ASX.
Read More
CSL Reaping The Reward Of Foresight
CSL has shown foresight in expanding plasma collection over recent years, enabling significant share in a market where demand for immunoglobulin has run ahead of supply.
Read More
Analyst Views
CSL – Credit Suisse rates the stock as Outperform
Credit Suisse believes the pandemic will promote a sustained increase in flu vaccination rates over the next 2-3 years.
Read More
CSL – Morgan Stanley rates the stock as Equal-weight
CSL and the Australian government have signed a heads of agreement to supply doses of the University of Queensland's coronavirus vaccine, scheduled for distribution in mid 2021.
Read More
CSL – UBS rates the stock as Buy
UBS reviews implications for plasma collection with the rise in coronavirus cases in certain US states. The broker expects a decline of -20% on average from April-September 2020 and then no growth until March 2021.
Read More
CSL – Macquarie rates the stock as Neutral
CSL has entered into a licensing agreement with uniQure for exclusive rights to a gene therapy product for haemophilia B.
Read More
CSL – Morgan Stanley rates the stock as Equal-weight
CSL Behring has obtained exclusive rights to develop and commercialise uniQure’s gene therapy candidate for Hemophilia B. Morgan Stanley expects CSL to pay uniQure more than US$2bn including $450m cash.
Read More